# Antidiuretic Hormone: Function and Regulation Antidiuretic hormone (ADH) is a nine-amino-acid peptide hormone, also called arginine vasopressin (AVP), that is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus, stored in the posterior pituitary, and released into circulation to increase water reabsorption by the renal collecting ducts. Its release is triggered primarily by a rise in plasma osmolality above roughly 280 to 290 mOsm/kg and secondarily by a fall in effective circulating volume. ADH is the single most important endocrine regulator of free water balance in mammals. When it fails, the kidney cannot concentrate urine, and an animal can lose many liters of water per day. When it is inappropriately high, water is retained and plasma sodium falls. Both directions of failure are clinically important in dogs and cats, and both appear in the veterinary literature. Understanding the ADH pathway is the foundation for interpreting polyuria, polydipsia, hypernatremia, and hyponatremia in practice. ## What ADH Is and Where It Comes From ### Synthesis in the hypothalamus ADH is produced by two paired clusters of magnocellular neurosecretory neurons in the hypothalamus: the supraoptic nuclei and the paraventricular nuclei. These neurons are unusual in that they behave as both nerve cells and endocrine cells. They receive synaptic input from osmoreceptors and baroreceptors, generate action potentials, and package their peptide product into large dense-core vesicles. The gene product is a preprohormone. After cleavage, the mature ADH nonapeptide is packaged together with two carrier proteins: neurophysin II and a glycopeptide called copeptin. All three are released together in equimolar amounts, which is why copeptin has attracted interest as a surrogate marker of ADH secretion. A recent review of central and nephrogenic diabetes insipidus describes copeptin as a promising surrogate marker that may simplify and improve diagnostic accuracy in the future [1]. The same hypothalamic neurons that make ADH also make oxytocin in adjacent cell groups. Because the two systems sit so close together, damage to the AVP system can also affect oxytocin. A randomized trial protocol notes that oxytocin deficiency has been identified in patients with AVP deficiency and is linked to increased anxiety and impaired emotion recognition [2]. This anatomical proximity is a useful reminder that the posterior pituitary is not a simple storage sac but the terminal field of two distinct hypothalamic systems. ### Storage in the posterior pituitary ADH travels down the axons of the supraoptic and paraventricular neurons through the pituitary stalk and accumulates in axon terminals in the posterior pituitary (neurohypophysis). The posterior pituitary does not synthesize ADH. It stores it. This distinction matters clinically. A lesion that destroys the cell bodies in the hypothalamus causes permanent ADH deficiency. A lesion that only interrupts the stalk may cause transient deficiency because the severed axons can sometimes regenerate and re-establish storage. Magnetic resonance imaging of the pituitary region reflects this storage. The posterior pituitary normally shows a bright signal on T1-weighted images, often called the posterior pituitary bright spot, which corresponds to stored ADH. Loss of that bright spot is a recognized imaging sign of central ADH deficiency. In a case of lymphocytic infundibulo-neurohypophysitis, MRI showed pituitary stalk thickening and absence of the posterior pituitary bright signal, supporting a central cause of diabetes insipidus [3]. ## Release Triggers and Sensors ADH release is controlled by two main classes of input: osmotic and non-osmotic. ### Osmotic regulation Specialized osmoreceptor neurons, located in the circumventricular organs of the hypothalamus where the blood-brain barrier is permeable, sense plasma osmolality. When plasma osmolality rises above the normal threshold of approximately 280 to 290 mOsm/kg, these cells shrink, fire more rapidly, and drive ADH release. The relationship is steep. Small increases in osmolality produce large increases in plasma ADH, and the kidney responds by concentrating urine. The osmotic threshold is not fixed. It can shift with pregnancy, with chronic illness, and with age. This is why a plasma osmolality that would normally suppress ADH can still be associated with measurable hormone in some animals. ### Non-osmotic regulation The second major trigger is a fall in effective circulating volume. Baroreceptors in the carotid sinus, aortic arch, and atria sense stretch. When blood volume or pressure falls, baroreceptor firing decreases, and the loss of inhibitory input allows ADH release. This pathway is less sensitive than the osmotic pathway. A substantial volume deficit, often quoted as a loss of roughly 5 to 10 percent of blood volume, is needed before ADH rises appreciably from baroreceptor input alone. However, once activated, the volume pathway can override osmotic suppression. This is why a severely dehydrated animal may continue to release ADH even when plasma osmolality is not elevated. Other non-osmotic stimuli include pain, nausea, stress, hypoxia, hypercapnia, angiotensin II, and several drugs. A case report on disrupted ACTH and cortisol responses notes that during stress, AVP enhances corticotropin-releasing hormone-stimulated ACTH secretion [4]. This links ADH to the hypothalamic-pituitary-adrenal axis and explains why ADH is sometimes described as a stress hormone as well as a water-balance hormone. ### Feedback loop summary The ADH system is a classic negative feedback loop. The table below lays out the components. | Stimulus | Sensor | Effector | Response | |--|--|--|--| | Plasma osmolality above 280 to 290 mOsm/kg | Hypothalamic osmoreceptor neurons | Supraoptic and paraventricular neurons | Increased ADH release from posterior pituitary | | Decreased effective circulating volume | Carotid, aortic, and atrial baroreceptors | Supraoptic and paraventricular neurons | Increased ADH release, often overriding osmotic suppression | | Increased ADH in plasma | V2 receptors on collecting duct principal cells | cAMP signaling and aquaporin-2 insertion | Increased water reabsorption, concentrated urine | | Restoration of plasma osmolality and volume | Hypothalamic osmoreceptors and baroreceptors | Reduced ADH release | Decreased aquaporin-2, dilute urine, water excretion | This loop explains why plasma osmolality stays within a narrow range in healthy animals despite wide variation in water intake. ## V2 Receptor Signaling and Aquaporin-2 ADH acts on three receptor subtypes. V1a receptors mediate vasoconstriction and some hepatic effects. V1b receptors are in the anterior pituitary and help regulate ACTH. V2 receptors are the ones that control water balance, and they are the focus here. ### The signaling cascade V2 receptors are G-protein-coupled receptors located on the basolateral membrane of principal cells in the collecting duct of the kidney. When ADH binds V2, the receptor activates a stimulatory G protein, which activates adenylyl cyclase. Adenylyl cyclase converts ATP to cyclic AMP (cAMP). cAMP activates [protein kinase](/knowledge/molecular-biology/protein-kinase) A, which phosphorylates aquaporin-2 water channels stored in intracellular vesicles. Phosphorylated aquaporin-2 vesicles traffic to the apical membrane and fuse with it, inserting water channels into the luminal surface. Water then moves from the tubular lumen into the principal cell through aquaporin-2, and exits the basolateral membrane through aquaporin-3 and aquaporin-4, which are constitutively present. The result is osmotic water reabsorption driven by the medullary concentration gradient. When ADH falls, aquaporin-2 is retrieved from the apical membrane by endocytosis, and water reabsorption stops. This is a fast, reversible system. Aquaporin-2 can be inserted or removed within minutes, which is why urine concentration can change quickly after a water load or a period of deprivation. ### Why the medullary gradient matters Aquaporin-2 insertion only works if the renal medulla is hypertonic. The medullary gradient is generated by the loop of Henle and maintained by the vasa recta. If the medulla is damaged or the gradient is washed out, water cannot be reabsorbed even if ADH signaling is intact. This is the mechanism behind osmotic diuresis and some forms of acquired nephrogenic diabetes insipidus. A study of patients with sickle cell anemia illustrates the distinction. In that cohort, 82 percent had elevated fasting ADH values and low fasting urine osmolality, but none had polyuria and free water clearance was negative in all cases. The authors concluded that the urine concentration defect was due to osmotic diuresis from an impaired medullary gradient rather than a lesion of the collecting tubule [5]. In other words, high ADH and a damaged medullary gradient can coexist, and the result is not true nephrogenic diabetes insipidus. ## Diabetes Insipidus: Central Versus Nephrogenic Diabetes insipidus is the clinical syndrome that results when ADH is deficient or when the kidney cannot respond to it. The two main categories are central and nephrogenic. ### Central diabetes insipidus Central diabetes insipidus (CDI) results from inadequate ADH synthesis or release. Causes include congenital malformation of the hypothalamus or pituitary, traumatic or surgical damage to the pituitary stalk, infiltrative disease, autoimmune hypophysitis, and tumors such as craniopharyngioma, germ cell tumor, or lymphoma. A case of a 2-year-old castrated male domestic shorthair cat with severe lethargy, dehydration, and hypernatremia was found on MRI to have partial hypoplasia or aplasia of the hypothalamus and pituitary gland. This confirmed congenital central diabetes insipidus, and the cat was managed long term with gradually titrated oral desmopressin [6]. This is a rare presentation in an adult cat and shows that congenital central disease can remain occult until adulthood. Postoperative CDI is a well-documented complication of transsphenoidal surgery. A case report describes a patient who developed polyuria exceeding 1000 mL per hour within hours of pituitary adenoma removal, with urine osmolality of 213.3 mOsm/kg and serum sodium of 149 mmol/L [7]. The report notes that most cases resolve within a few days, but severe cases with extremely high urine output do occur. The same principle applies in veterinary neurosurgery: damage to the neurohypophyseal stalk or hypothalamus can produce transient or permanent CDI. Autoimmune hypophysitis is another cause. A case report emphasizes that it should be considered in the differential diagnosis of central diabetes insipidus and that it carries long-term implications [8]. In [veterinary medicine](/blog/careers/veterinary-medicine-careers-from-clinical-practice-to-public-health), lymphocytic hypophysitis is recognized in dogs and can present with polyuria and polydipsia. ### Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus (NDI) results from renal resistance to ADH. The congenital form is most often caused by X-linked mutations in the AVPR2 gene, which encodes the V2 receptor. A case report describes a 17-month-old male infant with severe hypernatremia, dehydration, vomiting, and failure to thrive. Initial findings and a partial response to desmopressin suggested central diabetes insipidus, but persistent polyuria despite escalating desmopressin doses prompted reconsideration. Genetic testing confirmed a pathogenic AVPR2 mutation, establishing congenital NDI [9]. This case illustrates a common diagnostic trap: a partial response to desmopressin does not rule out nephrogenic disease. A three-decade retrospective study of pediatric NDI found that all patients presented with polydipsia, polyuria, and failure to thrive. The median diuresis was 10.0 mL/kg/h, median serum sodium at diagnosis was 160.5 mmol/L, and the urine-to-plasma osmolality ratio was 0.41. All desmopressin tests were negative [10]. These findings are consistent with the veterinary pattern: marked polyuria, hypernatremia when water access is limited, and no response to exogenous ADH. Acquired NDI is more common in veterinary practice than the congenital form. Causes include chronic kidney disease, pyelonephritis, hypercalcemia, hypokalemia, and drug toxicity. The mechanism is either downregulation of aquaporin-2, interference with the medullary gradient, or both. ### Comparison table | Feature | Central diabetes insipidus | Nephrogenic diabetes insipidus | |--|--|--| | Primary defect | Deficient ADH synthesis or release | Renal resistance to ADH | | Common causes | Hypothalamic or pituitary lesions, trauma, autoimmune disease, congenital malformation | AVPR2 or AQP2 mutations, chronic kidney disease, hypercalcemia, hypokalemia, drugs | | Response to desmopressin | Present | Absent or partial | | Urine osmolality after water deprivation | Low, rises with desmopressin | Low, does not rise with desmopressin | | Plasma ADH or copeptin | Low | High or normal | | Typical species examples | Dogs, cats, and reported in an adult cat with hypothalamic aplasia [6] | Congenital in humans via AVPR2 mutation [9], acquired forms common in dogs and cats | ## How ADH Function Is Tested ### Water deprivation test The water deprivation test is the traditional gold standard for distinguishing central diabetes insipidus, nephrogenic diabetes insipidus, and primary polydipsia. The patient is deprived of water while urine osmolality, body weight, and serum sodium are monitored. In a normal animal, urine osmolality rises progressively as ADH is released. In central diabetes insipidus, urine remains dilute and then concentrates after desmopressin administration. In nephrogenic diabetes insipidus, urine remains dilute even after desmopressin. The test is not without pitfalls. A case of central diabetes insipidus after COVID-19 describes a patient in whom urine osmolality remained low with water deprivation, plasma ADH responses to hypertonic saline were blunted, and urine osmolality increased in response to desmopressin [3]. This pattern is textbook central disease. However, the same report notes that MRI showed pituitary stalk thickening and absence of the posterior pituitary bright spot, which supported the diagnosis but was not definitive on its own. The most common pitfalls in veterinary practice are: - **Primary polydipsia.** An animal that drinks excessively for behavioral or psychogenic reasons has a washed-out medullary gradient and may not concentrate urine fully during deprivation. This can mimic central or nephrogenic diabetes insipidus. Prolonged deprivation may be required, and the test must be supervised. - **Partial central diabetes insipidus.** Some animals retain enough ADH to concentrate urine partially. The response to desmopressin may be partial, which can be misread as nephrogenic disease. - **Partial nephrogenic diabetes insipidus.** Some animals have a partial response to desmopressin, which can be misread as central disease. The case report of the infant with AVPR2 mutation is a clear example [9]. - **Dehydration risk.** Water deprivation can cause severe hypernatremia and azotemia. The test should be stopped if body weight falls by a predetermined percentage or if the animal becomes clinically unstable. - **Concurrent disease.** Chronic kidney disease, hypercalcemia, and hypokalemia can impair urine concentration independently of ADH. These must be ruled out before interpreting the test. ### Copeptin and other markers Copeptin is released in equimolar amounts with ADH and is more stable in plasma. A review of central and nephrogenic diabetes insipidus describes copeptin as a promising surrogate marker that may simplify and improve diagnostic accuracy [1]. In veterinary medicine, copeptin assays are not yet widely available, but the concept is relevant because direct ADH measurement is technically difficult. ## Clinical Relevance, Limitations and Common Mistakes ADH disorders matter in veterinary practice because polyuria and polydipsia are among the most common presenting complaints in dogs and cats. The differential list is long, and ADH-related disease sits alongside chronic kidney disease, diabetes mellitus, hyperadrenocorticism, pyometra, and liver disease. A structured approach is essential. The first step is to confirm true polyuria. Owners often overestimate urine volume. Measuring water intake over 24 hours and, where possible, collecting urine over 24 hours gives objective data. In the pediatric NDI study, median diuresis was 10.0 mL/kg/h, which is far above normal [10]. In a case of postoperative CDI, urine output exceeded 1000 mL per hour [7]. These numbers illustrate the magnitude of the problem. The second step is to assess hydration and electrolyte status. Hypernatremia is a red flag for water loss or water deprivation. In the NDI study, median serum sodium at diagnosis was 160.5 mmol/L [10]. In the adult cat with central diabetes insipidus, severe hypernatremia was present until desmopressin therapy was initiated [6]. Hypernatremia in a polyuric animal suggests either limited water access or a severe concentrating defect. The third step is to distinguish central from nephrogenic disease. The water deprivation test with desmopressin challenge remains the standard, but it must be interpreted carefully. A partial response does not exclude nephrogenic disease, and a poor response does not exclude central disease if the animal is dehydrated or has concurrent renal disease. Common mistakes include: - **Assuming all polyuria is diabetes insipidus.** Diabetes mellitus, chronic kidney disease, and hyperadrenocorticism are far more common. - **Interpreting a partial desmopressin response as proof of central disease.** The AVPR2 case shows that partial responses occur in nephrogenic disease [9]. - **Forgetting that the medullary gradient can be washed out.** Primary polydipsia and osmotic diuresis can produce dilute urine without true ADH deficiency or resistance [5]. - **Missing the transition from ADH deficiency to ADH excess.** A case report describes a patient who initially presented with central diabetes insipidus and later developed SIADH after tumor regression, highlighting that the same hypothalamic-pituitary disease can produce opposite syndromes at different times [11]. A similar report describes a patient with hypothalamic lymphoma who fluctuated between SIAD and DI [12]. In veterinary patients with hypothalamic or pituitary disease, repeated assessment may be necessary. - **Overlooking non-osmotic stimuli.** Pain, stress, and nausea can raise ADH and confound interpretation of osmolality-based tests. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## Quick Review - ADH is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus and stored in the posterior pituitary. - Release is triggered by plasma osmolality above 280 to 290 mOsm/kg and by volume depletion via baroreceptors. - V2 receptors on collecting duct principal cells signal through cAMP to insert aquaporin-2 into the apical membrane. - Central diabetes insipidus is ADH deficiency. Nephrogenic diabetes insipidus is renal resistance to ADH. - The water deprivation test with desmopressin challenge is the traditional diagnostic standard, but partial responses can mislead. - Hypernatremia in a polyuric animal suggests a severe concentrating defect or limited water access. - The same hypothalamic-pituitary lesion can cause ADH deficiency, ADH excess, or both over time. ## Frequently Asked Questions ### What is antidiuretic hormone? Antidiuretic hormone is a peptide made in the hypothalamus and released from the posterior pituitary that tells the kidney to reabsorb water. It is also called arginine vasopressin. ### What triggers ADH release? A rise in plasma osmolality above about 280 to 290 mOsm/kg is the main trigger. A fall in effective circulating volume also triggers release through baroreceptors. ### How does ADH work in the kidney? ADH binds V2 receptors on collecting duct cells, raises cAMP, and causes aquaporin-2 water channels to move to the cell surface. Water then moves out of the urine and back into the body. ### What is the difference between central and nephrogenic diabetes insipidus? Central diabetes insipidus is a lack of ADH. Nephrogenic diabetes insipidus is a failure of the kidney to respond to ADH. Both cause polyuria and polydipsia, but they respond differently to desmopressin. ### Can diabetes insipidus be cured? Some cases are transient, especially after surgery or injury, and resolve on their own. Congenital and chronic cases usually require long-term management. A veterinarian can determine the cause and the appropriate plan. ### Why does my pet drink so much water? Excessive water intake can be caused by diabetes insipidus, diabetes mellitus, kidney disease, hormonal disease, or behavioral polydipsia. Measuring water intake and urine output is the first step toward a diagnosis. ```mermaid flowchart TD A[Plasma osmolality rises] --> B[Hypothalamic osmoreceptors fire] B --> C[ADH released from posterior pituitary] C --> D[ADH binds V2 receptor] D --> E[cAMP rises in collecting duct cell] E --> F[Aquaporin-2 inserts into apical membrane] F --> G[Water reabsorbed from urine] G --> H[Plasma osmolality falls] H --> I[ADH release decreases] I --> J[Aquaporin-2 removed] J --> K[Dilute urine excreted] ``` ## Related Articles - [Spliceosome Proteins: Composition, Function, and Regulation](/knowledge/molecular-biology/spliceosome-proteins) - [Operon in Bacteria: Structure, Function, and Regulation](/knowledge/molecular-biology/operon-in-bacteria) - [Lac Operon: Structure, Function, and Regulation in E. coli](/knowledge/molecular-biology/lac-operon) - [Ara Operon: Structure, Function, and Regulation in E. coli](/knowledge/molecular-biology/ara-operon) - [Operon Promoter: Structure, Function, and Regulation in Prokaryotes](/knowledge/molecular-biology/operon-promoter) - [Histone Deacetylase: Function, Mechanism, and Role in Gene Regulation](/knowledge/molecular-biology/histone-deacetylase) - [Citric Acid Cycle: Steps, Products, and Regulation](/knowledge/molecular-biology/citric-acid-cycle-steps-products-and-regulation) - [c-Myc Gene: Function, Regulation, and Cancer Role](/knowledge/molecular-biology/c-myc-gene-function-regulation-and-cancer-role) - [Adrenal Cortex: Zones, Hormones and Function](/knowledge/veterinary-medicine/veterinary-anatomy-physiology/adrenal-cortex-zones-hormones-and-function) ## Sources 1. [Central and nephrogenic diabetes insipidus: updates on diagnosis and management.](https://pubmed.ncbi.nlm.nih.gov/39845881/) 2. [Oxytocin substitution therapy in patients with AVP deficiency (central diabetes insipidus): study protocol of a double-blind, randomised placebo-controlled trial.](https://pubmed.ncbi.nlm.nih.gov/42082227/) 3. [A case of central diabetes insipidus after COVID-19 as a probable diagnosis of lymphocytic infundibulo-neurohypophysitis with positive anti-rabphilin-3A antibodies with review of literature.](https://pubmed.ncbi.nlm.nih.gov/39198191/) 4. [Disrupted ACTH and cortisol response to osmotic and non-osmotic stress in patients with arginine vasopressin deficiency.](https://pubmed.ncbi.nlm.nih.gov/40498919/) 5. [Urine concentration impairment in sickle cell anemia: genuine nephrogenic diabetes insipidus or osmotic diuresis?](https://pubmed.ncbi.nlm.nih.gov/38059298/) 6. [Presumed partial aplasia of the hypothalamus and pituitary gland causing central diabetes insipidus in an adult cat.](https://pubmed.ncbi.nlm.nih.gov/42261486/) 7. [Severe Transient Central Diabetes Insipidus After Pituitary Adenoma Removal With Peak Urine Output of 33.5 L in 24 h.](https://pubmed.ncbi.nlm.nih.gov/42110191/) 8. [Autoimmune Hypophysitis: A Cause of Central Diabetes Insipidus.](https://pubmed.ncbi.nlm.nih.gov/40213755/) 9. [Infant Nephrogenic Diabetes Insipidus: Challenges Leading to Delayed Management.](https://pubmed.ncbi.nlm.nih.gov/42344104/) 10. [Nephrogenic Diabetes Insipidus: Three Decades of Clinical Reality.](https://pubmed.ncbi.nlm.nih.gov/40922895/) 11. [[From syndrome of inappropriate antidiuretic hormone secretion deficiency to excess - Challenges and solutions in a unique case].](https://pubmed.ncbi.nlm.nih.gov/42704014/) 12. [Syndrome of Inappropriate Antidiuresis and Diabetes Insipidus as Two Sides of the Same Coin in Hypothalamic Lymphoma: A Case Report.](https://pubmed.ncbi.nlm.nih.gov/36424791/)